FAVERIN

This brand name is authorized in Albania, Australia, Cyprus, Hong Kong SAR China, Ireland, Malta, Singapore, South Africa, Turkey, UK.

Active ingredients

The drug FAVERIN contains one active pharmaceutical ingredient (API):

1	Fluvoxamine UNII 5LGN83G74V - FLUVOXAMINE MALEATE
	The mechanism of action of fluvoxamine is thought to be related to selective serotonin re-uptake inhibition in brain neurones. There is minimum interference with noradrenergic processes. Receptor binding studies have demonstrated that fluvoxamine has negligible binding capacity to alpha adrenergic, beta adrenergic, histaminergic, muscarine cholinergic, dopaminergic or serotonergic receptors.
	Read more about Fluvoxamine

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
FAVERIN Film-coated tablet	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
N06AB08	Fluvoxamine	N Nervous system → N06 Psychoanaleptics → N06A Antidepressants → N06AB Selective serotonin reuptake inhibitors
Discover more medicines within N06AB08

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AL	Fondi i Sigurimit të Detyrueshëm të Kujdesit Shëndetësor	621/181
AU	Pharmaceutical Benefits Scheme	8174F, 8512B
GB	Medicines & Healthcare Products Regulatory Agency	26115, 26145
HK	Department of Health Drug Office	41397, 41398
IE	Health Products Regulatory Authority	22748, 23183
MT	Medicines Authority	MA1507/01001, MA1507/01002, PI1438/06601A, PI1438/06602A, PI770/12601A, PI770/12602A
SG	Health Sciences Authority	09489P, 09491P
TR	İlaç ve Tıbbi Cihaz Kurumu	8699820090012, 8699820090029
ZA	Health Products Regulatory Authority	33/1.2/0354